What is the fair value of DRREDDY's?
Dr. Reddy's Laboratories fair value assessments by pharmaceutical equity analysts establish average 1-year price targets reflecting its strong competitive positioning in global generic drugs, biosimilars, and active pharmaceutical ingredients. Valuation models incorporate complex generic product pipelines, North American market pricing pressures, regulatory compliance standards, and steady operational cash flows driving long-term intrinsic worth across global healthcare markets.
Related FAQs
Dr. Reddy's Laboratories Ltd is a leading, globally recognized Indian pharmaceutical company.
Realtek Semiconductor Corporation operates as a fabless semiconductor design enterprise, generating its substantial revenue primarily through the conception, development, and global marketing of integrated circuits.
No, Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company with its headquarters in Hyderabad, India. While it maintains a significant operational and commercial presence in the United States—including a U.S.
Financial institutions and equity research analysts tracking Dr. Reddy's Laboratories Limited (RDY) establish consensus 12-month average share price targets hovering around 1,500.00 to 1,600.00 Indian rupees per share.
Dr. Reddy's Laboratories has set a bold strategic goal to significantly expand its global reach by the year 2030. The company’s stated objective is to triple its existing impact to touch the lives of over 1.5 billion patients globally.
Dr. Reddy's Laboratories is widely considered a trusted pharmaceutical brand with a strong international reputation.
While specific numeric "global rankings" for pharmaceutical companies fluctuate based on the criteria used—such as total revenue, market cap, or R&D output—Dr.
Dr. Reddy's Laboratories is currently analyzed as having strong fundamentals, with valuation estimates suggesting it is fairly valued as of late July 2026.
There have been no new stock split announcements for Dr. Reddy's Laboratories in 2026.
As of July 2026, analysis of Dr. Reddy's Laboratories' stock based on Price-to-Earnings (PE) ratios indicates that it is currently overvalued compared to its historical 5-year average PE.
The name Eisai—referring to the major multinational Japanese pharmaceutical corporation—is correctly pronounced in standard Japanese as /eː.sa.i/, or roughly "eh-sah-ee".
Dr. Reddy's Laboratories Limited American Depositary Shares trade on the New York Stock Exchange under the ticker symbol RDY at a live market price of approximately $12.03 per share.
The share price of Dr. Reddy's Laboratories Limited (traded on the National Stock Exchange of India under the ticker DRREDDY) is approximately 1,169.00 INR. Dr.
Dr. Reddy's Laboratories maintains a resilient future outlook shaped by its diversified global footprint across North American generics, emerging market branded formulations, and biosimilars.
Dr. Reddy's Laboratories is a prominent Indian multinational pharmaceutical company globally renowned for developing, manufacturing, and marketing a vast portfolio of affordable generic medications, active pharmaceutical ingredients, and biosimilars.
The cost of "really good" or high-quality health insurance varies dramatically depending on the plan tier (Gold vs. Platinum), individual demographics (age, location), and whether the coverage is employer-sponsored or purchased individually.
As of August 2026, Dr. Reddy's Laboratories has secured U.S. FDA approval for its rituximab biosimilar, which was announced on August 1, 2026.
Based on salary data for 2026, employees at dsm-firmenich in India earn an average of approximately ₹47.0 lakhs per year. Salaries for the profiles reported generally range between ₹46.8 lakhs and ₹47.
Market consensus recommendations for Dr. Reddy's Laboratories (NYSE: RDY) reflect a balanced mix of hold and moderate buy ratings among international pharmaceutical equity research analysts.